InterCure and Cannasoul Forge Strategic Partnership to Innovate Cannabis Therapeutics
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Intercure ( (IL:INCR) ) is now available.
On November 3, 2025, InterCure Ltd. announced a strategic partnership with Cannasoul R&D Ltd., a leader in cannabis research. The agreements include a Share Purchase Agreement granting InterCure a 28% stake in Cannasoul, with potential to increase to 51%, and a Collaboration Agreement to advance cannabis therapeutics. This collaboration positions InterCure to capitalize on potential regulatory changes in the U.S. cannabis market, enhancing its scientific leadership and expanding its international footprint.
The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs499.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.
More about Intercure
InterCure Ltd., operating as Canndoc, is a leading cannabis company outside North America, recognized as Israel’s largest licensed cannabis producer. The company offers GMP-certified pharmaceutical-grade medical cannabis products and leverages a vertically integrated ‘seed-to-sale’ model to maintain a strong market presence globally.
YTD Price Performance: -21.40%
Average Trading Volume: 73,850
Technical Sentiment Signal: Strong Sell
Current Market Cap: ILs251.6M
See more data about INCR stock on TipRanks’ Stock Analysis page.
